Table 2:
Data represent patients included in this study with relevant clinical and demographic data as well as samples available from each of the three ileal and colon biopsy sites.
| VARIABLE | UC/IBDU (%), N=114 | CD (%), N=101 | HC (%), N=48 |
|---|---|---|---|
| MALE | 64 (56%) | 52 (51%) | 30 (62.5%) |
| MEDIAN AGE (YRS, RANGE) | 36 (18-72) | 28 (17-56) | 56 (31-71) |
| MEDIAN AGE AT DIAGNOSIS (YRS, RANGE) | 25 (11-59) | 20 (5-57) | |
| SMOKER (CURRENT) | 10 (9%) | 9(9%) | 3 (6%) |
| WHITE (SELF-DESCRIBED ETHINICITY) | 90 (79%) | 91 (90%) | 47 (98%) |
| MONTREAL CLASS | |||
| A1 | 24 (21%) | 35 (35%) | - |
| A2 | 69 (61%) | 57 (58%) | - |
| A3 | 16 (14%) | 9 (7%) | - |
| UNKNOWN | 5 | 2 | - |
| B1 | - | 21 (21%) | - |
| B2 | - | 20 (20%) | - |
| B3 | - | 60 (60%) | - |
| PERIANAL | - | 28 (28%) | - |
| L/E1 | 13 (11%) | 15 (15%) | - |
| L/E2 | 32 (28%) | 22 (22%) | - |
| L/E3 | 69 (61%) | 64 (64%) | |
| MEDICATIONS | |||
| METHOTREXATE | 0 | 11 (11%) | - |
| AZATHIOPRINE/6-MP | 13 (11%) | 20 (20%) | - |
| ANTI-TNF BIOLOGIC | 20 (17.5%) | 33 (33%) | - |
| ANTI-INTEGRIN BIOLOGIC | 1 (1%) | 1 (1%) | - |
| STEROIDS (ORAL) | 11 (10%) | 2 (2%) | - |
| SURGERY (INTRAABDOMINAL) | - | 20 (20%) | - |
| EXTRA-INTESTINAL MANIFESTATIONS | 19 (16.5%) | 20 (19.8%) | - |